Akero Therapeutics, Inc.

Historical 13F Holders

Symbol
AKRO
CUSIP
00973Y108
All holders as of
Q4 2025
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 00973Y108 since 12/18/2024, newest first.

Filer % of Class Filed
RTW Investments, LP 13G/A Amendment 4
0% 2/17/2026
Event 12/31/2025
Janus Henderson Group PLC 13G/A Amendment 12 4.1% 2/17/2026
Event 12/31/2025
Deep Track Capital, LP 13G/A Amendment 1
0% 2/13/2026
Event 12/31/2025
Wellington Management Group LLP 13G/A Amendment 1
0% 2/10/2026
Event 12/31/2025
Janus Henderson Group PLC 13G/A Amendment 11 7.9% 11/14/2025
Event 9/30/2025
Price T Rowe Associates Inc /MD/ 13G/A Amendment 2 4.8% 11/14/2025
Event 9/30/2025
Wellington Management Group LLP 13G
5.3% 11/12/2025
Event 9/30/2025
Deep Track Capital, LP 13G
5.5% 10/7/2025
Event 9/30/2025
RTW Investments, LP 13G/A Amendment 3
7.3% 8/14/2025
Event 6/30/2025
Janus Henderson Group PLC 13G/A Amendment 10 8.5% 8/14/2025
Event 6/30/2025
Wellington Management Group LLP 13G/A Amendment 4
4.3% 8/12/2025
Event 6/30/2025
General Atlantic, L.P. 13G/A Amendment 1
8.4% 5/15/2025
Event 3/31/2025
Janus Henderson Group PLC 13G/A Amendment 9 8.9% 5/14/2025
Event 3/31/2025
Wellington Management Group LLP 13G/A Amendment 3
7.5% 5/12/2025
Event 3/31/2025
Janus Henderson Group PLC 13G/A Amendment 8 8.7% 2/14/2025
Event 12/31/2024
RTW Investments, LP 13G/A Amendment 2
9.8% 2/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2025 Q4 2 20.0 k $533 k
2025 Q3 293 91.7 M $4.36 B
2025 Q2 290 92.2 M $4.92 B
2025 Q1 263 86.5 M $3.51 B
2024 Q4 205 74.2 M $2.06 B
2024 Q3 185 73.6 M $2.11 B
2024 Q2 165 74.1 M $1.74 B
2024 Q1 194 74.2 M $1.88 B
2023 Q4 178 60.9 M $1.42 B
2023 Q3 221 57.9 M $2.94 B
2023 Q2 182 56.7 M $2.65 B
2023 Q1 175 48.1 M $1.84 B
2022 Q4 187 51.2 M $2.80 B
2022 Q3 173 51.0 M $1.73 B
2022 Q2 115 36.7 M $330 M
2022 Q1 106 35.2 M $499 M
2021 Q4 104 35.4 M $749 M
2021 Q3 107 28.0 M $626 M
2021 Q2 101 27.7 M $701 M
2021 Q1 119 31.5 M $914 M
2020 Q4 102 30.9 M $816 M
2020 Q3 109 29.0 M $892 M
2020 Q2 83 21.9 M $545 M
2020 Q1 70 22.1 M $468 M
2019 Q4 59 19.1 M $423 M
2019 Q3 56 12.7 M $288 M
2019 Q2 49 10.7 M $205 M